Cambridge Investment Research Advisors
BRTX icon

Cambridge Investment Research Advisors’s BioRestorative Therapies BRTX Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,050
Closed -$77K – 3165
2022
Q4 		$77K Buy
28,050
+5,050
+22% +$15.7K ﹤0.01% 2941
2022
Q3 		$74K Hold
23,000
– – ﹤0.01% 2899
2022
Q2 		$68K Sell
23,000
-1
-0% -$4 ﹤0.01% 2911
2022
Q1 		$120K Buy
+23,001
New +$99.3K ﹤0.01% 2987

Other funds holding BRTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cambridge Investment Research Advisors's BRTX Position: Q1 2023 in Review

Cambridge Investment Research Advisors sold out of BioRestorative Therapies (BRTX) in Q1 2023, closing a stake of 28,050 shares — an estimated $77K sold.

Cambridge Investment Research Advisors first reported a position in BRTX in Q1 2022 and held it in 4 quarters. The position peaked at $120K in Q1 2022. 14 funds tracked by Wall St. Rank hold BRTX as of Q1 2023.

  • Cambridge Investment Research Advisors reported no remaining BioRestorative Therapies position as of Q1 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 28,050 BioRestorative Therapies shares in Q1 2023, an estimated $77K.
  • Cambridge Investment Research Advisors first reported a position in BioRestorative Therapies in Q1 2022 and held it in 4 quarters.
  • Cambridge Investment Research Advisors's BioRestorative Therapies position peaked at $120K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q1 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2023, filed 11 May 2023.